Connolly Hospital
- Address
- lock Available on a paid plan
Immune System Diseases
The Rheumatology Department at Connolly Hospital focuses on immune system disorders. Conditions include systemic lupus erythematosus. Research also examines Addison’s disease. A further target is active idiopathic inflammatory myopathy.
- Systemic Lupus Erythematosus
- Addison’s Disease
- Active Idiopathic Inflammatory Myopathy
- Systemic Sclerosis
Trials evaluate new agents for reducing disease activity, enhancing quality of life, and stabilising immune function.
Musculoskeletal Diseases
Studies address musculoskeletal disease. One focus is active idiopathic inflammatory myopathy. Another interest is the impact of disease on systemic sclerosis.
- Active Idiopathic Inflammatory Myopathy
- Systemic Sclerosis
The aim is to test innovative treatments that preserve muscle strength and reduce chronic pain while monitoring long‑term safety.
Respiratory Tract Diseases
The site investigates respiratory tract diseases. Key conditions include idiopathic pulmonary fibrosis and progressive pulmonary fibrosis.
- Idiopathic Pulmonary Fibrosis
- Progressive Pulmonary Fibrosis
Studies aim to slow the decline in forced vital capacity and improve overall lung health.
Digestive System Diseases
Research targets digestive system disease. The primary focus is ulcerative colitis.
- Moderately to severely active ulcerative colitis
Trials compare emerging oral agents with standard care to achieve endoscopic improvement and lasting symptomatic remission.
Nutritional and Metabolic Diseases
The department also studies nutritional and metabolic disorders. A central condition is obesity.
- Obesity
Objectives include evaluating weight reduction, metabolic marker changes, and overall cardiovascular safety.
Skin and Connective Tissue Diseases
Investigations include skin and connective tissue disease. A major focus is systemic sclerosis.
- Systemic Sclerosis
Clinical work aims to protect lung function, improve skin scores, and reduce the overall disease burden.
Site Overview
Activity Indicator
Last 6 months
Trial Flow
How this site's trials are distributed across therapeutic areas and active substances (IMPs), and how they're positioned within their overall lifecycle status. Flow thickness represents the number of unique trials.
Top 5 of 9 therapeutic areas and 15 of 44 IMPs, ranked by number of trials.
Compounds & Molecules Timeline
The time span of clinical-trial activity for the main active substances (IMPs) studied at this site over the last 8 years. Each bar runs from the earliest trial start to the most recent end; a substance with a trial still open has no recorded end and is shown as ongoing.
Top 40 of 44 compounds, ranked by number of trials.
Sponsor & Partnership
Top sponsors by active trials, and the ones that have come back for more than one study.
Sponsor Network
Top 9 by active trials.
- 1Boehringer Ingelheim Espana S.A.3active
lock +8 more on a paid plan
Partnership History
Sponsors with repeated collaboration (≥ 2 trials).
- 1Boehringer Ingelheim Espana S.A.5trials
lock +7 more on a paid plan
Sponsor Network Graph
How sponsors and therapeutic areas connect across this site's active trials: each link is at least one active trial shared between them, and bigger nodes mean more activity. Click a node to see its exact connections.
Country Benchmark
Compared to 45 other sites in Ireland
Therapeutic Area Benchmark — Ireland
Select a therapeutic area to compare against other sites in Ireland.
Competitor Comparison
Similar sites in the same country running a comparable number of trials (within ±30%), scored on how closely their trial portfolios match this one. Higher percentages mean a more similar profile.
Country: Ireland
Market Share
Country: Ireland
Therapeutic Area Market Share
Select a therapeutic area to view its disease coverage breakdown.
Heat Maps & Advanced Analytics
How often specific conditions appear in trials across this site and comparable sites from the same country. Each row is a site, each column a condition, and each cell the number of trials on it — darker means more activity.
Other Trials in Connolly Hospital
lock Showing 1 of 28 trials — the rest is available on a paid plan.
| Trial | Sponsor | Phase | Status | Start Date | End Date |
|---|---|---|---|---|---|
| A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD | Boehringer Ingelheim Espana S.A., Boehringer Ingelheim International GmbH, Boehringer Ingelheim RCV GmbH & Co. KG | Phase III | Not Recruiting | Jan 2024 | Jun 2026 |
IMP list
lock Showing 1 of 44 compounds — the rest is available on a paid plan.
| IMP | Trials | Status | First start | Last start |
|---|---|---|---|---|
| Efgartigimod Alfa | 3 | Unknown | 2023-03-01 | 2025-04-15 |
Upgrade this site to Business Plan
Own the profile, publish your feasibility data and reach sponsors directly.
Is something out of date?
Tell us what needs correcting and we'll update this profile.
lock Available to Business plan sites only.